Efficacy of Brexpiprazole in Participants with Agitation Associated with Dementia Due to Alzheimer’s Disease: Pooled Analysis of Randomized Controlled Trials
Key Points
Brexpiprazole shows a significant reduction in agitation associated with dementia.
In pooled analyses of trials, participants demonstrated improved scores for agitation symptoms.
This analysis involved a comprehensive review of randomized controlled trials focused on Alzheimer's-related agitation.
Findings suggest brexpiprazole may enable better management strategies for agitation in dementia patients.
Abstract
ClinicalTrials.gov identifiers: NCT01862640, NCT03548584, and NCT01922258.
Efficacy of Brexpiprazole in Participants with Agitation Associated with Dementia Due to Alzheimer’s Disease: Pooled Analysis of Randomized Controlled Trials | Synapse